[Kanamycin and florimycin in the clinical course of pulmonary tuberculosis].
D000293:Adolescent; D000328:Adult; D000419:Albuminuria / Q000139:chemically induced; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D003523:Cycloserine / Q000627:therapeutic use; D003864:Depression, Chemical; D004352:Drug Resistance, Microbial; D004802:Eosinophilia / Q000139:chemically induced; D005000:Ethionamide / Q000627:therapeutic use; D006261:Headache / Q000139:chemically induced; D006311:Hearing Disorders / Q000139:chemically induced; D006417:Hematuria / Q000139:chemically induced; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D007612:Kanamycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008171:Lung Diseases / Q000188:drug therapy; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D011537:Pruritus / Q000139:chemically induced; D011718:Pyrazinamide / Q000627:therapeutic use; D012138:Respiratory Therapy; D013610:Tachycardia / Q000139:chemically induced; D013882:Thiosemicarbazones / Q000627:therapeutic use; D013997:Time Factors; D014012:Tinnitus / Q000139:chemically induced; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014717:Vertigo / Q000139:chemically induced; D014722:Vestibule, Labyrinth / Q000187:drug effects; D014756:Viomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D013882:Thiosemicarbazones; D011718:Pyrazinamide; D007612:Kanamycin; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D014756:Viomycin
Kanamitsin i florimitsin v klinike legochnogo tuberkuleza.